November 16, 2016

Palbociclib and Letrozole in Advanced Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Finn et al. (Wed,) studied this question.

synapsesocial.com/papers/69d89a5d183921ebcaae2cbf https://doi.org/https://doi.org/10.1056/nejmoa1607303

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,512 citations
2Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy2012 · 27 citations
3Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study2015 · 133 citations
4Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts2004 · 1,244 citations
5The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice2013 · 378 citations

Preguntar a la IA

Me gusta

Guardar